GENB Generate Biomedicines, Inc.

GENB Generate Biomedicines, Inc.

Healthcare · Biotechnology

Market read

POC $12.94 · VWAP $13.94 · +12.6% vs 12m avg buyer

too-young churn: quiet as of

Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)

Coverage

1 related perspective

GENB Price Structure

Loading chart…

Loading timeframes…

Peers

Every watchlist GENB belongs to, members best 30-day change first — GENB highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.

Next earnings GENB reports in 79 days Nov 5

Against street estimates

How GENB's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.

2 quarters on file · newest report Aug 6 · projection Aug 17

Result
Aug 6 -0.50-0.52-4.0%Miss
May 7 -0.51-1.07-111.2%Miss

News (last pull)

Headlines about GENB from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.

pulled 58 days ago · Jun 21

GENB research tape

2 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.

Types
Aug 6 Catalyst GENB earnings